Proteomic characterization of the interstitial fluid perfusing the breast tumor microenvironment: a novel resource for biomarker and therapeutic target discovery

Research output: Contribution to journalJournal articleResearchpeer-review

Standard

Proteomic characterization of the interstitial fluid perfusing the breast tumor microenvironment : a novel resource for biomarker and therapeutic target discovery. / Celis, Julio E; Gromov, Pavel; Cabezón, Teresa; Moreira, José Manuel Alfonso; Ambartsumian, Noona; Sandelin, Kerstin; Rank, Fritz; Gromova, Irina.

In: Molecular and Cellular Proteomics, Vol. 3, No. 4, 2004, p. 327-44.

Research output: Contribution to journalJournal articleResearchpeer-review

Harvard

Celis, JE, Gromov, P, Cabezón, T, Moreira, JMA, Ambartsumian, N, Sandelin, K, Rank, F & Gromova, I 2004, 'Proteomic characterization of the interstitial fluid perfusing the breast tumor microenvironment: a novel resource for biomarker and therapeutic target discovery', Molecular and Cellular Proteomics, vol. 3, no. 4, pp. 327-44. https://doi.org/10.1074/mcp.M400009-MCP200

APA

Celis, J. E., Gromov, P., Cabezón, T., Moreira, J. M. A., Ambartsumian, N., Sandelin, K., Rank, F., & Gromova, I. (2004). Proteomic characterization of the interstitial fluid perfusing the breast tumor microenvironment: a novel resource for biomarker and therapeutic target discovery. Molecular and Cellular Proteomics, 3(4), 327-44. https://doi.org/10.1074/mcp.M400009-MCP200

Vancouver

Celis JE, Gromov P, Cabezón T, Moreira JMA, Ambartsumian N, Sandelin K et al. Proteomic characterization of the interstitial fluid perfusing the breast tumor microenvironment: a novel resource for biomarker and therapeutic target discovery. Molecular and Cellular Proteomics. 2004;3(4):327-44. https://doi.org/10.1074/mcp.M400009-MCP200

Author

Celis, Julio E ; Gromov, Pavel ; Cabezón, Teresa ; Moreira, José Manuel Alfonso ; Ambartsumian, Noona ; Sandelin, Kerstin ; Rank, Fritz ; Gromova, Irina. / Proteomic characterization of the interstitial fluid perfusing the breast tumor microenvironment : a novel resource for biomarker and therapeutic target discovery. In: Molecular and Cellular Proteomics. 2004 ; Vol. 3, No. 4. pp. 327-44.

Bibtex

@article{e33618a0e9d44cfbbbd72dd7b2bdf5bb,
title = "Proteomic characterization of the interstitial fluid perfusing the breast tumor microenvironment: a novel resource for biomarker and therapeutic target discovery",
abstract = "Clinical cancer proteomics aims at the identification of markers for early detection and predictive purposes, as well as to provide novel targets for drug discovery and therapeutic intervention. Proteomics-based analysis of traditional sources of biomarkers, such as serum, plasma, or tissue lyzates, has resulted in a wealth of information and the finding of several potential tumor biomarkers. However, many of these markers have shown limited usefulness in a clinical setting, underscoring the need for new clinically relevant sources. Here we present a novel and highly promising source of biomarkers, the tumor interstitial fluid (TIF) that perfuses the breast tumor microenvironment. We collected TIFs from small pieces of freshly dissected invasive breast carcinomas and analyzed them by two-dimensional polyacrylamide gel electrophoresis in combination with matrix-assisted laser desorption/ionization time-of-flight mass spectrometry, Western immunoblotting, as well as by cytokine-specific antibody arrays. This approach provided for the first time a snapshot of the protein components of the TIF, which we show consists of more than one thousand proteins--either secreted, shed by membrane vesicles, or externalized due to cell death--produced by the complex network of cell types that make up the tumor microenvironment. So far, we have identified 267 primary translation products including, but not limited to, proteins involved in cell proliferation, invasion, angiogenesis, metastasis, inflammation, protein synthesis, energy metabolism, oxidative stress, the actin cytoskeleton assembly, protein folding, and transport. As expected, the TIF contained several classical serum proteins. Considering that the protein composition of the TIF reflects the physiological and pathological state of the tissue, it should provide a new and potentially rich resource for diagnostic biomarker discovery and for identifying more selective targets for therapeutic intervention.",
keywords = "Adult, Aged, Aged, 80 and over, Blotting, Western, Breast Neoplasms, Electrophoresis, Gel, Two-Dimensional, Extracellular Fluid, Female, Gene Expression Profiling, Humans, Middle Aged, Neoplasm Invasiveness, Peptide Fragments, Peptide Mapping, Perfusion, Proteome, Proteomics, Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization, Tumor Markers, Biological",
author = "Celis, {Julio E} and Pavel Gromov and Teresa Cabez{\'o}n and Moreira, {Jos{\'e} Manuel Alfonso} and Noona Ambartsumian and Kerstin Sandelin and Fritz Rank and Irina Gromova",
year = "2004",
doi = "10.1074/mcp.M400009-MCP200",
language = "English",
volume = "3",
pages = "327--44",
journal = "Molecular and Cellular Proteomics",
issn = "1535-9476",
publisher = "American Society for Biochemistry and Molecular Biology",
number = "4",

}

RIS

TY - JOUR

T1 - Proteomic characterization of the interstitial fluid perfusing the breast tumor microenvironment

T2 - a novel resource for biomarker and therapeutic target discovery

AU - Celis, Julio E

AU - Gromov, Pavel

AU - Cabezón, Teresa

AU - Moreira, José Manuel Alfonso

AU - Ambartsumian, Noona

AU - Sandelin, Kerstin

AU - Rank, Fritz

AU - Gromova, Irina

PY - 2004

Y1 - 2004

N2 - Clinical cancer proteomics aims at the identification of markers for early detection and predictive purposes, as well as to provide novel targets for drug discovery and therapeutic intervention. Proteomics-based analysis of traditional sources of biomarkers, such as serum, plasma, or tissue lyzates, has resulted in a wealth of information and the finding of several potential tumor biomarkers. However, many of these markers have shown limited usefulness in a clinical setting, underscoring the need for new clinically relevant sources. Here we present a novel and highly promising source of biomarkers, the tumor interstitial fluid (TIF) that perfuses the breast tumor microenvironment. We collected TIFs from small pieces of freshly dissected invasive breast carcinomas and analyzed them by two-dimensional polyacrylamide gel electrophoresis in combination with matrix-assisted laser desorption/ionization time-of-flight mass spectrometry, Western immunoblotting, as well as by cytokine-specific antibody arrays. This approach provided for the first time a snapshot of the protein components of the TIF, which we show consists of more than one thousand proteins--either secreted, shed by membrane vesicles, or externalized due to cell death--produced by the complex network of cell types that make up the tumor microenvironment. So far, we have identified 267 primary translation products including, but not limited to, proteins involved in cell proliferation, invasion, angiogenesis, metastasis, inflammation, protein synthesis, energy metabolism, oxidative stress, the actin cytoskeleton assembly, protein folding, and transport. As expected, the TIF contained several classical serum proteins. Considering that the protein composition of the TIF reflects the physiological and pathological state of the tissue, it should provide a new and potentially rich resource for diagnostic biomarker discovery and for identifying more selective targets for therapeutic intervention.

AB - Clinical cancer proteomics aims at the identification of markers for early detection and predictive purposes, as well as to provide novel targets for drug discovery and therapeutic intervention. Proteomics-based analysis of traditional sources of biomarkers, such as serum, plasma, or tissue lyzates, has resulted in a wealth of information and the finding of several potential tumor biomarkers. However, many of these markers have shown limited usefulness in a clinical setting, underscoring the need for new clinically relevant sources. Here we present a novel and highly promising source of biomarkers, the tumor interstitial fluid (TIF) that perfuses the breast tumor microenvironment. We collected TIFs from small pieces of freshly dissected invasive breast carcinomas and analyzed them by two-dimensional polyacrylamide gel electrophoresis in combination with matrix-assisted laser desorption/ionization time-of-flight mass spectrometry, Western immunoblotting, as well as by cytokine-specific antibody arrays. This approach provided for the first time a snapshot of the protein components of the TIF, which we show consists of more than one thousand proteins--either secreted, shed by membrane vesicles, or externalized due to cell death--produced by the complex network of cell types that make up the tumor microenvironment. So far, we have identified 267 primary translation products including, but not limited to, proteins involved in cell proliferation, invasion, angiogenesis, metastasis, inflammation, protein synthesis, energy metabolism, oxidative stress, the actin cytoskeleton assembly, protein folding, and transport. As expected, the TIF contained several classical serum proteins. Considering that the protein composition of the TIF reflects the physiological and pathological state of the tissue, it should provide a new and potentially rich resource for diagnostic biomarker discovery and for identifying more selective targets for therapeutic intervention.

KW - Adult

KW - Aged

KW - Aged, 80 and over

KW - Blotting, Western

KW - Breast Neoplasms

KW - Electrophoresis, Gel, Two-Dimensional

KW - Extracellular Fluid

KW - Female

KW - Gene Expression Profiling

KW - Humans

KW - Middle Aged

KW - Neoplasm Invasiveness

KW - Peptide Fragments

KW - Peptide Mapping

KW - Perfusion

KW - Proteome

KW - Proteomics

KW - Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization

KW - Tumor Markers, Biological

U2 - 10.1074/mcp.M400009-MCP200

DO - 10.1074/mcp.M400009-MCP200

M3 - Journal article

C2 - 14754989

VL - 3

SP - 327

EP - 344

JO - Molecular and Cellular Proteomics

JF - Molecular and Cellular Proteomics

SN - 1535-9476

IS - 4

ER -

ID: 41043775